On a quest to chal­lenge No­vo Nordisk in obe­si­ty, transpa­cif­ic start­up picks up $70M — and a pair of sea­soned ex­ecs

4 years ago
People
Financing

In­hi­brx shares rise on PhI tri­al re­sults; Bragli­a's Helsinn en­ters part­ner­ship with Fo­s­un

4 years ago
News Briefing

Take­da en­lists Po­sei­da in $3.6B+ non­vi­ral gene ther­a­py deal, though da­ta re­main years away from hu­man stud­ies

4 years ago
Deals
Cell/Gene Tx

Ace­to keeps up spend­ing spree with ac­qui­si­tion of Ire­land's A&C

4 years ago
Deals

Top Sanofi vac­cine ex­ecs, Bris­tol My­ers vet chart new path for IG­M's an­ti­bod­ies in in­fec­tious dis­eases, au­toim­mu­ni­ty

4 years ago
People

J&J sci­ence lead Paul Stof­fels set to re­tire amid brain trust shake­up at world's largest drug­mak­er

4 years ago
People

Covid-19 roundup: Ex­perts wor­ry mol­nupi­ravir de­mand will leave poor coun­tries be­hind as Mer­ck says it will dou­ble ...

4 years ago
Coronavirus

IPO flood­gates open up af­ter sum­mer lull as five more biotechs file for Nas­daq

4 years ago
Financing

Sci­en­tist be­hind Mer­ck­'s Covid pill: We need to watch out for re­sis­tance

4 years ago
R&D
Coronavirus

As Con­gress bat­tles over gov­ern­ment drug price ne­go­ti­a­tion, new poll finds strong sup­port on both sides of the aisle

4 years ago
Pharma

GSK and Vir turn to US for dis­tri­b­u­tion as Covid-19 mAb treat­ment nears block­buster sta­tus

4 years ago
Coronavirus

In quick turn­around, FDA lifts full clin­i­cal hold on Pro­tag­o­nist's blood can­cer pro­gram

4 years ago
FDA+

Draw­ing Shire par­al­lel, Flem­ming Ørn­skov mulls IPO for Gal­der­ma; Rei­s­tone shows re­sults from eczema study with JAK1 ...

4 years ago
News Briefing

Post-split GSK to ex­it mar­quee world HQ, blue­print­ing small­er cor­po­rate digs

4 years ago
Pharma

Su­per­nus ex­pands its port­fo­lio of Parkin­son's drugs with a $400M+ buy­out

4 years ago
Financing
Deals

The End­points 100 gives a C-suite thumbs down on 'crip­pling' price pro­pos­als and Aduhelm. Plus: Is any­one go­ing to JP ...

4 years ago
Bioregnum
Special

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

4 years ago
R&D

Flex­ion heads to the dis­count aisle for a $450M+ merg­er with Paci­ra

4 years ago
Deals

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

4 years ago
R&D

Covid-19 roundup: Mer­ck sub­mits mol­nupi­ravir for EUA; In­dia re­sumes vac­cine ex­ports af­ter Delta surge

4 years ago
Coronavirus

Af­ter fil­ing for au­tho­riza­tion of its Covid-19 an­ti­body as a pro­phy­lac­tic, As­traZeneca pulls out new da­ta in the ...

4 years ago
R&D
Coronavirus

Af­ter three decades and a sur­prise re­jec­tion, first treat­ment for ba­bies born with­out a thy­mus se­cures FDA ap­proval

4 years ago
Cell/Gene Tx
FDA+

Search­ing for the next 'big hairy goal,' Blue­Rock CEO Emile Nuwaysir jumps to in vi­vo cell ther­a­py start­up En­so­ma

4 years ago
People
Cell/Gene Tx

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; ...

4 years ago
Weekly
First page Previous page 638639640641642643644 Next page Last page
A service from the Financial Times